BusinessGeoVax Reports 2018 First Quarter Financial Results and Development Program UpdatesBy Nasdaq OMXMay 3, 2018, 5:00 PM UTC
BusinessVBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B VaccineBy Nasdaq OMXApr 19, 2018, 12:00 PM UTC
BusinessVBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B VaccineBy Nasdaq OMXDec 19, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceBy Nasdaq OMXDec 12, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017By Nasdaq OMXNov 10, 2017, 1:00 PM UTC
BusinessVBI Vaccines Strengthens Board of Directors with Appointment of Ran NussbaumBy Nasdaq OMXNov 2, 2017, 12:02 PM UTC
BusinessVBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 MillionBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessVBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 MillionBy Nasdaq OMXOct 26, 2017, 1:29 PM UTC
